The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Impact of bridging therapy on the outcomes of patients with R/R myeloma treated with ide-cel
Aimaz Afrough, MD, UT Southwestern Medical Center, Dallas, TX, discusses the results of an analysis examining the impact of bridging therapy (BT) on clinical outcomes in patients with relapsed or refractory (R/R) multiple myeloma who received idecabtagene vicleucel (ide-cel). Whilst there was no difference in response and toxicity rates between patients who did or did not receive BT, patients who did not receive BT had a higher progression-free survival (PFS) and overall survival (OS), which is likely due to lower disease severity. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
